Fig. 4
From: Cancer testis antigen burden (CTAB): a novel biomarker of tumor-associated antigens in lung cancer
Kaplan–Meier overall survival analyses for cancer testis antigen burden (CTAB) high and low groups across various histological and treatment subgroups in the retrospective cohort: A All patients, B patients treated with pembrolizumab monotherapy, C patients treated with pembrolizumab in combination with chemotherapy, D patients with non-squamous NSCLC, E patients with non-squamous NSCLC treated with pembrolizumab monotherapy, F patients with non-squamous NSCLC treated with pembrolizumab in combination with chemotherapy. Statistical comparisons p-values indicated on each plot